Teva Pharmaceutical Industries (TEVA) FY2020 results: revenue $16.7 billion, down 1.4% on the year
Teva Pharmaceutical Industries Ltd. (TEVA) reported revenue of $16.7 billion for fiscal 2020, the year ended 31 December 2020, down 1.4% on the year before. Net income was -$4.0 billion, and diluted earnings per share $-3.64. The figures are the company's own, from the 10-K it filed with the SEC on 10 February 2021.
Revenue
$16.7 billion
-1.4% on the year
FY2013FY2020
Operating margin
-21.4%
-2.6% a year earlier
FY2013FY2020
Net income
-$4.0 billion
FY2013FY2020
Diluted EPS
-$3.64
FY2013FY2020
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Revenue
16,659
16,887
18,271
-1.4%
Cost of revenue
8,933
9,351
9,975
-4.5%
Gross profit
7,726
7,537
8,296
+2.5%
Gross margin
46.4%
44.6%
45.4%
Research and development
997
1,010
114
-1.3%
Operating income
-3,572
-443
-1,637
Operating margin
-21.4%
-2.6%
-9.0%
Interest expense
901
822
920
+9.6%
Pre-tax income
-4,406
-1,265
-2,596
Income tax
-168
-278
-195
Net income
-3,990
-999
-2,150
Net margin
-24.0%
-5.9%
-11.8%
Diluted EPS
-$3.64
-$0.91
-$2.35
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Operating cash flow
1,216
748
2,446
+62.6%
Capital expenditure
578
525
651
+10.1%
Free cash flow
638
223
1,795
+186.1%
Free cash flow margin
3.8%
1.3%
9.8%
Cash from investing
863
1,355
1,866
-36.3%
Cash from financing
-1,885
-1,926
-3,351
Depreciation and amortisation
1,557
1,722
1,842
-9.6%
Share-based compensation
129
119
155
+8.4%
Dividends paid
n/a
n/a
12.0
Dividend per share
n/a
$0.00
$0.00
Diluted shares, weighted
1,095m
1,091m
1,021m
+0.4%
Balance sheet
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Shareholders' equity
10,026
13,972
14,707
-28.2%
Non-controlling interest
1,035
1,091
1,087
-5.1%
Debt
25,919
26,907
28,916
-3.7%
Operating lease liabilities
479
435
n/a
+10.1%
Other liabilities
13,181
15,065
15,973
-12.5%
Total liabilities and equity
50,640
57,470
60,683
-11.9%
Fixed assets
6,296
6,436
6,868
-2.2%
Goodwill
20,624
24,846
24,917
-17.0%
Intangible assets
8,923
11,232
14,005
-20.6%
Cash and equivalents
2,177
1,975
1,782
+10.2%
Receivables
4,581
5,676
5,822
-19.3%
Inventory
4,403
4,422
4,731
-0.4%
Other assets
3,636
2,883
2,558
+26.1%
Total assets
50,640
57,470
60,683
-11.9%
10-K for the year ended 31 December 2020, filed 10 February 2021: the filing.